ProMIS CEO granted 160,000 stock options

ProMIS Neurosciences Inc. reported that Chief Executive Officer Neil K. Warma received a grant of stock options.

Rhea-AI Filing Summary

ProMIS Neurosciences Inc. reported that Chief Executive Officer Neil K. Warma received a grant of stock options. The award covers 160,000 options to buy common shares at an exercise price of $10.77 per share, expiring on May 20, 2036. According to the footnote, these options vest ratably over four years, contingent on his continued service with the company.

Insights

Equity Compensation Analyst

CEO receives routine four-year stock option grant as equity compensation.

The filing shows ProMIS Neurosciences’ CEO Neil K. Warma was granted 160,000 options with a $10.77 exercise price, expiring in 2036. The grant appears to be compensation rather than an open-market transaction.

The footnote states these options vest ratably over four years, subject to continued service. This encourages leadership retention and long-term alignment with shareholders. As a single compensation grant with no sales, it is generally a neutral event for existing investors.

Insider Trade Summary

Grant/Award: 160,000 shares

Grant/Award 1 txn

Insider Warma Neil K

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Option (right to buy)	160,000	$0.00	$0.00

Holdings After Transaction: Option (right to buy) — 160,000 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to this option shall vest ratably over four years, subject to continued service to the Issuer through each vesting date.

Key Figures

Options granted: 160,000 options Exercise price: $10.77 per share Expiration date: May 20, 2036 +3 more

6 metrics

Options granted 160,000 options Grant to CEO Neil K. Warma on May 20, 2026

Exercise price $10.77 per share Strike price for granted options

Expiration date May 20, 2036 Option term end date

Underlying shares 160,000 common shares Shares subject to the option grant

Vesting period 4 years Options vest ratably over four years

Shares following transaction (options) 160,000 options Total option holdings from this grant after transaction

Key Terms

Option (right to buy), Grant, award, or other acquisition, exercise price, vest ratably over four years, +1 more

5 terms

Option (right to buy) financial

"security_title: "Option (right to buy)""

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

exercise price financial

"conversion_or_exercise_price: "10.7700""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest ratably over four years financial

"The shares subject to this option shall vest ratably over four years"

Common Shares financial

"underlying_security_title: "Common Shares""

Common shares are the basic units of ownership in a company that give holders a claim on profits and a right to vote on key matters, like electing the board. Think of them as membership cards in a club: they let you share in successes and losses, but in a bankruptcy or liquidation they are paid after creditors and preferred shareholders, so their value can swing more and matters for assessing risk and potential return.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did ProMIS Neurosciences (PMN) report in this Form 4 for its CEO?

ProMIS Neurosciences reported that CEO Neil K. Warma received a grant of 160,000 stock options. These options give him the right to buy common shares at a fixed price, aligning part of his compensation with the company’s future share performance.

How many stock options did the ProMIS Neurosciences (PMN) CEO receive?

The CEO received 160,000 stock options. Each option represents the right to purchase one common share, providing potential upside if the share price later exceeds the option’s fixed exercise price of $10.77 per share over the option term.

What is the exercise price of the new ProMIS Neurosciences (PMN) CEO options?

The options carry an exercise price of $10.77 per share. This means the CEO can buy ProMIS Neurosciences common shares at $10.77 regardless of the future market price, once the options have vested and before they expire in 2036.

When do the ProMIS Neurosciences (PMN) CEO stock options expire?

The CEO’s stock options expire on May 20, 2036. He can only exercise vested options before that date. After the expiration date, any unexercised options become worthless and no longer provide the right to purchase common shares.

How do the ProMIS Neurosciences (PMN) CEO options vest over time?

The options vest ratably over four years, subject to the CEO’s continued service. Ratable vesting typically means a portion becomes exercisable each year, tying the economic benefit of the award to ongoing employment and long-term company performance.

Is the ProMIS Neurosciences (PMN) CEO Form 4 a stock purchase or compensation grant?

The Form 4 reflects a compensation-related grant, not an open-market stock purchase. The transaction code is “A” for a grant, award, or other acquisition, with 160,000 options awarded at an exercise price of $10.77 per share and no cash paid at grant.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/22/2026 - 04:34 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Warma Neil K

(Last) (First) (Middle)

C/O PROMIS NEUROSCIENCES INC.

SUITE 200, 1920 YONGE STREET

(Street)

TORONTO M4S 3E2

(City) (State) (Zip)

ONTARIO, CANADA

(Country)

2. Issuer Name and Ticker or Trading Symbol
ProMIS Neurosciences Inc. [ PMN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option (right to buy)	$10.77	05/20/2026		A		160,000		(1)	05/20/2036	Common Shares	160,000	$0	160,000	D

Explanation of Responses:

1. The shares subject to this option shall vest ratably over four years, subject to continued service to the Issuer through each vesting date.

	/s/ Max A. Milbury, Attorney in Fact for Neil Warma	05/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)